O.V. Knyazev, A.V. Kagramanova, I.A. Korneeva, K.K. Noskova, S.V. Belousov, A.I. Parfenov

Abstract


Aim. To compare fecal calprotectin (FC) concentration with laboratory and diagnostic methods in patients with inflammatory bowel diseases (IBD). Materials and methods. The level of FC was measured in 110 patients with established IBD. Crohn diseases (CD) was diagnosed in 50 patients, ileocolitis - in 38 and terminal ileitis in 12 individuals. Ulcerative colitis (UC) was diagnosed in 60 patients, total colitis in 35, left-side colitis in 21 and 4 patients have proctitis. Laboratory data include measurement of FC, leukocytes, erythrocyte sedimentation rate (ESR), C reactive protein (CRP), fecal occult blood. All patients underwent colonoileoscopy (CIS) at the start of disease flare and after 12 weeks of treatment. Results and discussion. We found linear correlation between level of FCP and endoscopic activity of CD, analyzing FCP level and endoscopic activity of CD before (during disease flare) and after 12 weeks treatment (r=0.66, p<0.001). Linear correlation between FCP and SES-CD sustained after 12 weeks of treatment (r=0.77, p<0.001). We revealed correlation between FCP concentration. And CRP level (r=0.59, p<0.05). The linear correlation was detected between FCP and endoscopic activity of UC (r=0.88, p<0.001) before the treatment. After 12 weeks of treatment linear correlation was shown between FCP and Meyo scale (r=0.73, p<0.001). IBD patients with FCP more than 200 mcg/g have high risk of disease reccurence in short-term period of time (HR - 8.33; 95% CI 2.05-33.8; χ2 - 11.85; p<0.001) and (HR - 2.7; 95% CI 1.1-6.6; χ2 - 5.3; p<0.05), accordingly. Conclusion. Increased FCP level indicates poor effectiveness of treatment and high risk of reccurence. The level of FCP correlates strongly with recent laboratory and diagnostic indices of activity and enables to determine patients with high risk of reccurence. Thus, thorough monitoring, including additional procedures, contributes to just-in-time treatment modification.

Full Text

Restricted Access

About the authors

O V Knyazev

A.S. Loginov Moscow Clinical Research and Practical Center of the Department of Health of Moscow

Moscow, Russia

A V Kagramanova

A.S. Loginov Moscow Clinical Research and Practical Center of the Department of Health of Moscow

Moscow, Russia

I A Korneeva

A.S. Loginov Moscow Clinical Research and Practical Center of the Department of Health of Moscow

Moscow, Russia

K K Noskova

A.S. Loginov Moscow Clinical Research and Practical Center of the Department of Health of Moscow

Moscow, Russia

S V Belousov

A.S. Loginov Moscow Clinical Research and Practical Center of the Department of Health of Moscow

Moscow, Russia

A I Parfenov

A.S. Loginov Moscow Clinical Research and Practical Center of the Department of Health of Moscow

Email: asfold@mail.ru
Moscow, Russia

References

  1. Фадеева Н.А., Корнеева И.А., Князев О.В., Парфенов А.И. Биомаркеры активности воспалительных заболеваний кишечника. Терапевтический архив. 2018;90(12):107-11. doi: 10.26442/00403660.2018.12.000018
  2. Hsu K, Champaiboon C, Guenther B.D, Sorenson B.S, Khammanivong A, Ross K.F, Geczy C.L, Herzberg M.C. Anti - infective protective properties of s100 calgranulins. Antiinflamm Antiallergy Agents Med Chem. 2009 Dec 4;8(4):290-305.
  3. Roseth A.G, Aadland E, Jahnsen J, Raknerud N. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion. 1997;58(2):176-80.
  4. Осипенко М.Ф., Ливзан М.А., Скалинская М.И., Лялюкова Е.А. Концентрация фекального кальпротектина в дифференциальной диагностике заболеваний кишечника. Терапевтический архив. 2015;87(2):30-3. doi: 10.17116/terarkh201587230-33
  5. Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro de Acosta M, Burisch J, Gecse K.B, Hart A.L, Hindryckx P, Langner C, Limdi J.K, Pellino G, Zagórowicz E, Raine T, Florian M.H. Third European Evidence - based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra - intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo - anal Pouch Disorders. J Crohn's Colitis. 2017;11(6):649-70. doi: 10.1093/ecco-jcc/jjx008
  6. Ивашкин В.Т., Шелыгин Ю.А., Халиф И.Л., Белоусова Е.А. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и ассоциации колопроктологов России по диагностике и лечению болезни Крона. Колопроктология. 2017;60(2):7-29.
  7. Ивашкин В.Т., Шелыгин Ю.А., Халиф И.Л., Белоусова Е.А. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению язвенного колита. Колопроктология. 2017;59(1):6-30.
  8. Annese V, Daperno M, Rutter М.D, et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis. 2013;7(12):982-1018. doi: 10.1016/j.crohns.2013.09.016
  9. Schroeder K.W, Tremaine W.J, Ilstrup D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625-9.
  10. Best W.R, Becktel J.M, Singleton J.W, Kern F. Jr. Development of a Crohnʹs disease activity index. National Cooperative Crohnʹs Disease Study. Gastroenterology. 1976;70(3):439-44.
  11. De Suray N, Salleron J, Vernier-Massouille G, Grimaud J.C, Bouhnik Y, Laharie D, Dupas J.L, Pillant H, Picon L, Veyrac M, Flamant M, Savoye G, Jian R, de Vos M, Piver E, Mary J.Y, Colombel J.F, Louis E. Close monitoring of CRP and fecal calprotectin levels to predict relapse in Crohn's disease patients. A sub analysis of the STORI study. J Crohn's Colitis. 2012;6(1):118-9. doi: 10.1016/S1873-9946(12)60294-3
  12. Van Rheenen P.F, van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta - analysis. BMJ. 2010;341:3369-80. doi: 10.1136/bmj.c3369
  13. Gisbert J.P. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis. 2009;41:56-66. doi: 10.1007/s00508-015-0915-3

Statistics

Views

Abstract - 33

PDF (Russian) - 13

Cited-By


PlumX

Dimensions

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:

 

© 2018 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies